Turning stats into outcomes
June 07, 2011
Novartis has received clearance in Europe to market its eye drug Lucentis for macular oedema secondary to retinal vein occlusion, a disease than can cause severe damage to the retina, visual impairment and ultimately blindness.
Allergan will no doubt be breathing a sigh of relief after cost regulators published final draft guidance endorsing its eye implant Ozurdex for use in National Health Service patients with macular oedema.
February 08, 2011
Cost regulators for the National Health Service in England and Wales have asked Allergan to provide more data on its macular oedema eye implant Ozurdex, particulary on how it compares to Roche/Genentech's Avastin.
PharmaTimes 2013 Copyright | RSS Feed Subscriptions